Allopurinol pharmacogenetics: assessment of potential clinical usefulness by Zineh Issam, Mummaneni Padmaja, Lyndly Jenna, Amur Shashi, La Grenade Lois A, Chang Stephen H, Rogers Hobart, Pacanowski Michael A in Pharmacogenomics (2011).

[PMID: 22118056] PubMed


Use of pharmacogenetics to inform treatment decisions remains a priority for clinicians, patients and public health agencies. We previously developed a framework for systematically assessing whether pharmacogenetic test information would likely bring value to clinical decision-making and enjoy practical uptake. We applied this tool to allopurinol to determine potential usefulness of HLA genetic information in assessing risk for allopurinol-induced severe cutaneous adverse reactions. We quantified allopurinol use data and the magnitude of adverse event signals using US FDA databases, reviewed reported cases of allopurinol-associated severe cutaneous adverse reactions to assess whether clinical subtypes of patients could be identified, performed pooled analyses of associations between HLA variation and allopurinol-induced severe cutaneous adverse reactions and described considerations in clinical implementation of allopurinol pharmacogenetics.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.